High-value oncology deals drive China’s drug licensing boom

China’s focus on first or best-in-class oncology drugs and innovative R&D will position it well in 2026 and beyond.

Howard Marks warned of an AI 'moonshot' mentality — and shared why he'd rather own tech titans than flashy startups

The Oaktree cofounder sees echoes of past bubbles in the current AI frenzy and urged investors to focus on durable, ...